DNLI vs. VCEL, APGE, KYMR, SANA, DNA, RXRX, FUSN, TWST, BEAM, and ACLX
Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Vericel (VCEL), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), Sana Biotechnology (SANA), Ginkgo Bioworks (DNA), Recursion Pharmaceuticals (RXRX), Fusion Pharmaceuticals (FUSN), Twist Bioscience (TWST), Beam Therapeutics (BEAM), and Arcellx (ACLX). These companies are all part of the "biological products, except diagnostic" industry.
Vericel (NASDAQ:VCEL) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.
Denali Therapeutics received 104 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 67.43% of users gave Denali Therapeutics an outperform vote while only 62.38% of users gave Vericel an outperform vote.
Vericel currently has a consensus target price of $46.40, indicating a potential downside of 2.70%. Denali Therapeutics has a consensus target price of $40.22, indicating a potential upside of 112.82%. Given Vericel's higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Vericel.
Vericel has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
92.9% of Denali Therapeutics shares are owned by institutional investors. 7.2% of Vericel shares are owned by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Vericel has higher earnings, but lower revenue than Denali Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vericel has a net margin of -1.61% compared to Vericel's net margin of -36.51%. Denali Therapeutics' return on equity of -1.55% beat Vericel's return on equity.
In the previous week, Denali Therapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 14 mentions for Denali Therapeutics and 13 mentions for Vericel. Denali Therapeutics' average media sentiment score of 0.74 beat Vericel's score of 0.20 indicating that Vericel is being referred to more favorably in the media.
Summary
Vericel and Denali Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Denali Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Denali Therapeutics Competitors List
Related Companies and Tools
